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Abstract Although the anticancer properties of extra virgin olive oil (EVOO) extracts have been recognized, the role of single compounds in non-melanoma skin cancer is still unknown. The in vitro chemopreventive and anticancer action of EVOO extracts and oil-derived compounds in non-melanoma skin cancer models were evaluated on cutaneous squamous cell carcinoma cells and on immortalized human keratinocytes stimulated with epidermal growth factor. Preparation of EVOO extracts and isolation of single compounds was carried out by chromatographic methods. Antitumor activity was assessed by cell-based assays (cell viability, migration, clonogenicity, and spheroid formation) and apoptosis documented by internucleosomal DNA fragmentation. Finally, inhibition of key oncogenic signaling nodes involved in the progression from actinic keratosis to cutaneous squamous cell carcinoma was studied by western blot. EVOO extracts reduced non-melanoma skin cancer cell viability and migration, prevented colony and spheroid formation, and inhibited proliferation of atypical keratinocytes stimulated with epidermal growth factor. Such a pharmacological activity was promoted by oleocanthal and oleacein through the inhibition of Erk and Akt phosphorylation and the suppression of B-Raf expression, whereas tyrosol and hydroxytyrosol did not have effect. The current study provides in vitro evidence for new potential clinical applications of EVOO extracts and/or single oil-derived compounds in the prevention and treatment of non-melanoma skin cancers.   
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polyphenol is represented by extra virgin olive oil (EVOO). The phenolic compounds identified in EVOO can be classified into three categories: simple phenols (such as tyrosol and hydroxytyrosol), secoiridoids (such as oleuropein, oleocanthal, and oleacein), and lignans. Several lines of evidence suggest that oleocanthal has anticancer activity in different types of tumors including hepatocellular carcinoma, multiple myeloma and breast, prostate and pancreatic cancer (Akl et al., 2014; Khanfar et al., 2015; LeGendre et al., 2015). Recently, our research group demonstrated that oleocanthal exerts cytotoxic activity against human malignant melanoma cells (Fogli et al., 2016).  The current work was aimed at evaluating the in vitro anticancer and chemopreventive potential of two EVOO extracts that differ in quantitative composition of simple compounds (tyrosol and hydroxytyrosol) and secoiridoid derivatives (oleocanthal and oleacein) on cutaneous non-melanoma skin cancer models. Specifically, the A431 squamous cell carcinoma cells overexpressing EGFR (Graness et al., 2000) was selected to test the anticancer activity of extracts and compounds, as previously reported (Kang et al., 2017). The  chemoprevention potential was assessed on immortalized (non-tumor) human keratinocytes (HaCaT) stimulated with EGF, a condition reproducing an in vitro microenvironment that favors the progression from actinic keratosis to cutaneous squamous cell carcinoma (Ratushny et al., 2012; Xiao et al., 2017). Finally, the activity of the secoiridoid derivatives, oleocanthal (OC) and oleacein (OA), and that of the simple phenols, tyrosol (T) and hydroxytyrosol (HT), were also investigated in the same experimental models.   
2. Materials and methods  













2.1.1 Chemical reagents and simple phenols Solvents used for the purification procedure, HPLC analyses, and NMR analyses were purchased from Sigma-Aldrich. Evaporation was carried out under vacuum using a rotating evaporator. Silica gel flash chromatography was performed using silica gel 60Å (0.040–0.063 mm; Merck). TLC analyses were carried out on Merck aluminum silica gel 
(60 F254) and were visualized under a UV lamp (λ = 254 nm) or by spraying with a 10% solution of phosphomolybdic acid in absolute ethanol. Preparative TLC (Prep TLC) purification was performed using either 2 mm (20 x 10) and 1 mm (10 x 10) glass-backed sheets precoated with silica gel 60 F254 purchased from VWR. p-hydroxyphenylacetic acid (as HPLC internal standard), tyrosol, and hydroxytyrosol were purchased from Sigma-Aldrich.  
2.1.2 Preparation of secoiridoid derivatives  The extraction and purification of oleocanthal and oleacein were developed using a previously reported procedure (Fogli et al., 2016). The purity of the secoiridoid derivatives was determined by 1H NMR, using a Bruker AVANCE IIITM 400 spectrometer (operating at 400 MHz) and HPLC analyses, using a Bechman HPLC instrument equipped with a system Gold UV/VIS Detector 166, setted to 278 nm. Separation was performed on a reverse phase C18 column Phenomenex using a mobile phase constituted by a mixture of H2O/AcOH (97.5:2.5 v/v) and MeOH/ACN (1:1 v/v).   













at 4,000 rpm for 5 min, at 25°C, the acetonitrile phase was collected, and evaporated under reduced pressure, to afford the phytoextracts P1 and P2. The oil extract was diluted with a mixture of methanol/water (1: 1 v/v) and injected in HPLC, for analysis. Phenolic compounds were identified by comparing their retention times and UV absorbance spectra with those of the authenticated standard and quantified at 278 nm using p-hydroxyphenylacetic acid as internal standard, according to previously reported method (Tasioula-Margari and Tsabolatidou, 2015). For each standard compound, the calibration curve was built and the detection limits (LOD) and quantification (LOQ) were estimated (Table 1). Sample concentrations were determined by linear regression. Correlation coefficients for each of the calibration curves were >0.99. 
 
2.2 Biology 
2.2.1 Cell lines  The human epidermoid carcinoma cell line A431 (ATCC, CRL-1555TM, Rockville, MD, USA) and human immortalized keratinocytes (HaCat) (ThermoFisher, Waltham, Massachusetts, USA) were cultured in DMEM (Euroclone, Euroclone, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Euroclone, Milan, Italy) at 37 °C with 5% CO2. A431-derived spheroids were cultured in DMEM/F12 (1:1) (Euroclone, Milan, Italy) supplemented with 20 ng/ml EGF (Sigma-Aldrich Milan, Italy), 0,4% BSA (Sigma-Aldrich, Milan, Italy) e 4 
μg/ml insulin (Sigma-Aldrich, Milan, Italy).   













Cell viability was measured using a method based on Neutral Red Assay (N2889, Sigma-Aldrich, Germany) following manufacturer's instructions. Briefly, cells (4×104/well) were seeded in 96-well plate in 10% FBS medium and after 24 h and complete medium was replaced by 1% FBS medium containing test compounds or vehicle. Phytoextracts was dissolved in DMSO (final concentration never exceeds 0.2%) and tested in a concentration range of 1-200 Pg/ml for 72 h. Oleocanthal, oleacein, tyrosol and hydroxytyrosol were dissolved in DMSO (final concentration never exceeds 0.2 %) and tested at 1-100 µM for 72 h. Further experiments were performed using extracts or single compounds at concentrations that approximate the IC50 mean values obtained in cell viability assays, as previously reported (Kang et al., 2017).  
2.2.3 Cell colony forming assay A431 were seeded at low density (500 cells/well) in 6-well plate with 10% FBS medium and treated after 24 h with phytoextracts at concentrations that induce 50% cell growth inhibition (IC50) in 1% FBS medium. After 10 days, colonies were washed twice with PBS, fixed with methanol for 20 min at -20°C, and stained with 0.05% crystal violet for 10 min at room temperature. Colonies containing >50 individual cells were counted under light microscopy. Pictures were taken at a 4× magnification. 
 













were washed twice with PBS to remove detached cells and incubated with phytoextracts at their corresponding IC50s. Cell migration was monitored by light microscopy (4× magnification) at different time points. The percentage decrease in the gap/darkness was calculated by using Image J software. 
 
2.2.5 Spheroid preparation A431 cells were seeded at low density (250 cells/well) in an optimized medium in 96-well plate coated with 1.5 % agarose to avoid cell adhesion. Cells were then treated with different concentrations of phytoextracts ranging from 1 to 200 Pg/ml for 72 h and monitored by light microscopy (4× magnification) after 10 d.  
 














2.2.8 Western blot Cell lysates were collected after treatment with phytoextracts or single compounds at their corresponding IC50s or vehicle for 30 min, as previously reported (Carpi et al., 2017). Samples (30 Pg-protein) were separated on a 10% SDS-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane by electro blotting (100 V, 1 h at 4°C), blocked with 5% non-fat milk in T-TBS (20 mM Tris, 500 mM NaCl, 0.1% Tween-20, pH 8) and probed with specific antibodies. Incubation was performed at 4°C overnight with anti-Erk 1/2 (Ref. sc-514302, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p-Erk (tyr-204) (Ref. sc-7383), anti-p-Akt1/2/3 (ser473) (Ref. Sc-7985-R, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-β-actin (Ref. #MAB1501, Merck Millipore, Darmstadt, Germany) antibodies. Membranes were then washed with blocking solution and probed with specific secondary antibodies. Quantification of proteins was performed using ImageJ densitometry software and signal intensities were 
normalized to those for β-actin.  
2.2.9 Statistical analysis All experiments were performed in triplicate and results analyzed by Prism 5 (GraphPad Software, San Diego, CA, USA). Data were shown as mean values ± standard error of the mean (SEM) obtained from at least three separate experiments. The IC50s were determined using nonlinear regression curve fit. The level of statistical significance was p<0.05. 
 
3. Results 













Phytoextracts (P1 and P2) were analyzed for their content in phenolic compounds (tyrosol and hydroxytyrosol) and secoiridoid derivatives (oleocanthal and oleacein). Total phenols content ranged from 400 ppm in P1 to 300 ppm in P2. For both phytoextracts, the amount of secoiridoid derivatives was higher than simple phenols. However, the ratio between secoiridoid compounds varied significantly in the two phytoextracts being 70% oleocanthal: 26% oleacein in P1, and 37% oleocanthal: 60% oleacein in P2. Simple phenols content was very low in both phytoextracts.           













after 24-48 h and there was an increased compactness over time (data not shown). The 10-d analysis showed the preventive action of phytoextracts at 30 μg/ml for 72 h on spheroid formation (see the high number of satellite cells when compared to untreated plates in Figure 1D). At 50 and 100 μg/ml, satellite colonies increased, and spheroids assumed a shape with less defined and irregular edges. At the maximum concentration tested (i.e., 200 μg/ml), the loss of spheroid compactness was shown by the presence of empty spaces into the spheroid core as well as the high number of satellite cells (Figure 1D). The mechanism of action were investigated by analyzing Erk and Akt phosphorylation and B-Raf expression in the presence or absence of phytoextracts at 35 and 45 μg/ml for P1 and P2, respectively. P1 and P2 decreased B-Raf levels by about 80 and 95%, p-Akt levels by 40 and 50%, and p-Erk expression by about 50 and 35%, respectively (Figure 2).   
3.3 Activity by single oil-derived compounds on A431 cells OC and OA at 0.1-100 μM for 72 h decreased A431 cell viability in a concentration-dependent manner (Figure 3A), with OA being the most active compound (Table 3). HT significantly reduced cell viability only at 100 μM (i.e., the maximum concentration tested), while the effect of T was negligible (Figure 3A; Table 3). Pro-apoptotic activity tested at concentrations that approximate their IC50 in cell viability assays (i.e., 30 μM 














3.4 Phytoextract activity on HaCat cells HaCat cells were stimulated or not with 5 ng/ml EGF and treated with tested phytoextracts at 1-200 μg/ml for 72 h. Concentration-dependent decrease in cell viability by phytoextracts was greater in stimulated than unstimulated cells; such an effect was particularly evident for P1, whereas P2 did not reach the IC50 at the maximum concentration tested (Figure 5; Table 4). Noteworthy, the maximum antitumor effect by phytoextracts was strongly increased after cells were cultured in phytoextracts-free medium for further 72 h (Figure 5; Table 4).  Western blot analysis demonstrated that phytoextracts significantly reduced B-Raf expression, and Erk 1/2 and Akt phosphorylation with no significant differences between them (Figure 6).   
3.5 Activity by single oil-derived compounds on EGF-stimulated HaCat cells  Single oil-derived compounds were tested at 0.1-100 μM for 72 h on EGF-stimulated cells (Figure 7A; Table 5). OC induced a concentration-dependent cell growth inhibition and was found to be more active than OA (Figure 7A; Table 5). HT also showed a concentration-dependent inhibitory effect with an IC50 close to the maximum tested 













did not reach the level of significance. Accordingly, OC and OA reduced Erk and AKT phosphorylation in a greater extent than HT and T (Figure 8).  
 


























To our knowledge, findings of the current study demonstrated for the first time the in vitro capability of OA to induce apoptosis in cSCC cells through inhibition of key signaling pathway. Experiments in our laboratory are ongoing to further investigate the anticancer properties of oleacein in other cancer cell lines.   In the attempt to understand whether concentrations of test compounds can correspond to relevant real-life doses as human skin olive oil-derived formulations, it is worth mentioning that the OC and OA amounts in the two EVOO extracts tested were comparable to those at their IC50s in single agent experiments (data not shown). T and HT levels found in EVOO extracts were instead very low and not sufficient to induce cytotoxicity. Biofortification procedures to increase the content of phenolic compounds, i.e., oleacein and oleocanthal, in EVOO extracts (D'Amato et al., 2017) may allow obtaining topic formulations enriched with secoiridoid derivatives worthy of being tested in non-melanoma skin cancer as chemopreventive and therapeutic agents. In conclusion, the current study provides a preclinical proof-of-concept for new potential topical applications of EVOO extracts and/or single oil-derived compounds in the prevention and treatment of non-melanoma skin cancers. 
 
















Table 1. Chromatographic method. Mobil phase Fractions Volume (ml) 














Table 2. Potency and maximum effect of phytoextracts after treatment of A431 cells for 72 h and followed by a growth with fresh phytoextracts-free medium (72+72 h).  IC50 (μg/ml ± SD)  Emax (% of cells ± SD)* 














Table 3. Potency and maximum effect of single compounds after treatment of A431 cells for 72 h. Compound IC50 (μM ± SD) Emax (% of cells ± SD)* OC 30 ± 1.1 10.5 ± 3.6 OA 10 ± 1.1 6.8 ± 3.1 HT >50 39 ± 90§ T >100 NR IC50: concentrations that induce 50% cell growth inhibition; Emax: maximum effect. *Emax values are expressed as a percentage of remaining tumor cells (the lower the value, the higher the maximum effect). §Mean value obtained at the maximum 














Table 4. Potency and maximum effect of phytoextracts after treatment of EGF-stimulated Hacat cells for 72 h and followed by a growth with fresh phytoextracts-free medium (72+72 h).  IC50 (μg/ml ± SD)  Emax (% of cells ± SD)* 
 72 h 144 h  72 h 144 h P1 61 ± 1.2 53.9 ± 1  20.2 ± 11.1 1 ± 2.6 P2 >200 43.1 ± 1  62.5 ± 29.9§ 3.6 ± 2.9 IC50: concentrations that induce 50% cell growth inhibition; Emax: maximum effect. *Emax values are expressed as a percentage of remaining tumor cells (the lower the value, the higher the maximum effect). §Mean value obtained at the maximum 














Table 5. Potency and maximum effect of single compounds after treatment of EGF-stimulated Hacat cells for 72 h. Compound  IC50 (μM ± SD) Emax (% of cells ± SD)* OC 26 ± 1.1 18.3 ± 7.2 OA 76 ± 3 33.4 ± 1.4§ HT ≈100 NR T >100 NR IC50: concentrations that induce 50% cell growth inhibition; Emax: maximum effect. *Emax values are expressed as a percentage of remaining tumor cells (the lower the value, the higher the maximum effect). §Mean value obtained at the maximum 













Figure legends  
Figure 1 Pharmacological activity of phytoextracts on A431 cells. (A) Cell viability A431 cells treated with phytoextracts (P1 and P2) at 1-200 μg/ml for 72 h or maintained for further 72 h in phytoextracts-free medium. (B) Colony formation assay after 10 d in cells treated with P1 and P2 at 35 and 45 μg/ml, respectively, as compared to controls,  (C) Scratch assay after 12 and 36 h in cells treated with phytoextracts at concentrations as colony formation assay, compared to controls. (D) Images of spheroid formation in treated (30-200 μg/ml) and control cells after 10 d and relative spheroid core densititometry. Data presented as mean ± SD of at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001, as compared to control (Student’s t-test or one-way 
ANOVA followed by Dunnetts’s test for multiple comparison).  
Figure 2 Western blot analysis of B-Raf, p-Erk, and p-Akt in A431 cells treated with phytoextracts. Cells were treated with phytoextract 1 (P1) and phytoextract 2 (P2) at 35 and 45 μg/ml, respectively, for 30 min. β-actin was used as a loading control. Data presented as mean ± SD of at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001, as compared to control (one-way ANOVA followed by Dunnetts’s multiple comparison test).  
Figure 3 Apoptosis by single oil-derived compounds on A431 cells. Cells were treated with 30 μM 













72 h. Data presented as mean ± SD of at least three independent experiments. ***p<0.001, as compared to control (one-way ANOVA followed by Dunnetts’s multiple comparison test).  
Figure 4 Western blot analysis of B-Raf, p-Erk, and p-Akt in A431 cells treated with single oil-derived compounds. Cells were treated with 30 μM OC, 10 μM OA, and 100 μM HT or T 
for 30 min. β-actin was used as a loading control. Data presented as mean ± SD of at least three independent experiments. *p<0.05, **p<0.01, as compared to control (one-
way ANOVA followed by Dunnetts’s multiple comparison test).  
Figure 5 Pharmacological activity of phytoextracts in HaCaT cells stimulated or not with 5 ng/ml EGF. Cell viability in stimulated and unstimulated cells treated with phytoextracts (P1 and P2) at 1-200 μg/ml for 72 h and in stimulated cells maintained for further 72 h in phytoextracts-free medium. Data presented as mean ± SD of at least three independent experiments.  
Figure 6 Western blot analysis of B-Raf, p-Erk, and p-Akt in EGF-stimulated HaCaT cells treated with phytoextracts. Cells were treated with P1 or P2 at 35 and 45 μg/ml, respectively, 













Figure 7 Apoptosis by single oil-derived compounds on HaCaT cells. Cells were treated with 25 
μM oleocanthal (OC), 100 μM oleacein (OA), hydroxytyrosol (HT) and tyrosol (T), for 72 h. Data presented as mean ± SD of at least three independent experiments.  
Figure 8 Western blot analysis of B-Raf, p-Erk, and p-Akt in EGF-stimulated HaCaT cells treated with single-oil derived compounds. Cells were treated with 25 μM oleocanthal (OC), 100 





















































x Extra virgin olive oil (EVOO) extracts exert anticancer activity on squamous cell carcinoma  
x EVOO extracts prevent proliferation of atypical human keratinocytes stimulated with EGF 
x EVOO extracts reduce protein expression of B-Raf and phosphorylation of Erk 1/2 and Akt  
x Oleocanthal and oleacein contribute to the anticancer effects by phytoextracts 
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